- 期刊
疑似Semaglutide導致急性膽囊炎之案例報告與文獻回顧
Suspected Semaglutide-Induced Cholecystitis: A Case Report and Literature Review
摘要
第一型類升糖素胜肽受體致效劑（Glucagon-like peptide-1 receptor agonists , GLP-1 RAs）已廣泛用於第二型糖尿病之治療，合併較少的低血糖風險，具體重減輕效果，且多數皮下注射長效型製劑施打頻率每週一次，更能提升用藥順從性。GLP-1 RAs會增加膽囊和膽道疾病相關不良反應，但國內僅liraglutide於藥品仿單的警語及注意事項提及急性膽囊疾病。本案例為49歲男性，皮下注射semaglutide 40週後發生急性膽囊炎症狀接受膽囊切除術，術後持續使用semaglutide之介紹。藉由報導此案例並探討GLP-1 RA藥物引起膽囊炎可能機轉，以期透過本案例提醒醫療人員留意藥物可能引發膽囊和膽道疾病相關藥物不良反應。
並列摘要
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used as a treatment for type 2 diabetes, have a low risk of hypoglycemia and the potential for weight loss, and most long-acting GLP-1 RAs are administered only once a week by subcutaneous injection, to improve medication adherence. However, using GLP-1RAs has been associated with an increased risk of adverse reactions related to bile duct and gallbladder diseases. In Taiwan, acute gallbladder disease is only listed on the Prescribing Information for liraglutide under the warnings and precautions section. This case was a 49-year-old male, undergoing cholecystectomy due to acute cholecystitis after being prescribed subcutaneous semaglutide for 40 weeks, and continuing subcutaneous semaglutide postoperatively. We aim to explore the factors and mechanisms of causing cholecystitis induced by GLP-IRAs and, thus, to increase the awareness of the potential adverse reactions of GLP-IRAs on the gallbladder and biliary tract.